Requirements for a lead compound to become a clinical candidate
2008

Requirements for a Lead Compound to Become a Clinical Candidate

publication Evidence: moderate

Author Information

Author(s): Franz F Hefti

Primary Institution: Avid Radiopharmaceuticals, Inc.

Conclusion

The path from lead to clinical drug candidate is complex and often unpredictable, requiring careful consideration of safety and efficacy.

Supporting Evidence

  • Drug candidates must bind selectively to target receptors and elicit desired responses.
  • The drug discovery process is complex and often unpredictable, with high attrition rates.
  • Safety and toxicity data are critical for regulatory approval of new drug candidates.

Takeaway

Finding a new medicine is like a treasure hunt where scientists look for special compounds that can help people, but it’s really hard and takes a long time.

Methodology

The review discusses the criteria and processes involved in selecting drug candidates for clinical testing, including safety evaluations and pharmacokinetic studies.

Potential Biases

Potential bias due to the author's affiliation with a pharmaceutical company.

Limitations

The review does not provide specific data or case studies to illustrate the discussed concepts.

Digital Object Identifier (DOI)

10.1186/1471-2202-9-S3-S7

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication